Democrats say intellectual property provisions in the deal are a boon to the pharmaceutical industry and could undermine their push to make American health care more affordable.
ANA SWANSON, NY Times: Business
Thu, 03/21/2019 - 3:59pm
Democrats say intellectual property provisions in the deal are a boon to the pharmaceutical industry and could undermine their push to make American health care more affordable.